$KPTI
Karyopharm Therapeutics Inc.

2018 Q1 Form 10-K Financial Statement

#000119312518084024 Filed on March 15, 2018

View on sec.gov

Income Statement

Concept 2018 Q1 2016 Q4 2016 Q3
Revenue $10.00M $47.00K $48.00K
YoY Change 14605.88% 88.0% -36.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.620M $6.540M $5.900M
YoY Change 21.73% 24.33% 23.95%
% of Gross Profit
Research & Development $41.32M $20.67M $19.89M
YoY Change 71.58% -14.09% -23.26%
% of Gross Profit
Depreciation & Amortization $170.0K $180.0K $180.0K
YoY Change -5.56% 5.88% 5.88%
% of Gross Profit
Operating Expenses $48.94M $27.21M $25.79M
YoY Change 61.27% -7.21% -15.95%
Operating Profit -$38.94M -$27.17M -$25.74M
YoY Change 28.61% -7.3% -15.9%
Interest Expense $510.0K $360.0K $310.0K
YoY Change 27.5% 44.0% 29.17%
% of Operating Profit
Other Income/Expense, Net $495.0K $369.0K $317.0K
YoY Change 28.57% 43.58% 33.76%
Pretax Income -$38.45M -$26.80M -$25.43M
YoY Change 28.61% -7.75% -16.28%
Income Tax $12.00K $140.0K
% Of Pretax Income
Net Earnings -$38.46M -$26.94M -$25.43M
YoY Change 28.55% -7.27% -16.29%
Net Earnings / Revenue -384.59% -57308.51% -52968.75%
Basic Earnings Per Share
Diluted Earnings Per Share -$775.4K -$650.4K -$690.7K
COMMON SHARES
Basic Shares Outstanding 49.65M shares 41.24M shares 35.99M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q1 2016 Q4 2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $130.9M $129.6M $126.8M
YoY Change 19.11% -26.2% -35.04%
Cash & Equivalents $37.50M $49.66M $43.91M
Short-Term Investments $93.40M $79.90M $82.90M
Other Short-Term Assets $2.400M $2.100M $3.400M
YoY Change 4.35% 5.0% 9.68%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $133.3M $131.6M $130.3M
YoY Change 18.79% -25.88% -34.33%
LONG-TERM ASSETS
Property, Plant & Equipment $2.454M $2.836M $2.991M
YoY Change -7.54% -18.58% -18.28%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $10.30M $45.40M $49.60M
YoY Change -74.44% 33.92% 44.19%
Other Assets $300.0K $500.0K $299.0K
YoY Change 1900.0% 0.0% 475.0%
Total Long-Term Assets $13.06M $48.75M $53.37M
YoY Change -69.77% 28.82% 38.17%
TOTAL ASSETS
Total Short-Term Assets $133.3M $131.6M $130.3M
Total Long-Term Assets $13.06M $48.75M $53.37M
Total Assets $146.4M $180.4M $183.6M
YoY Change -5.83% -16.27% -22.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.949M $4.751M $2.193M
YoY Change 16.58% 24.76% -51.99%
Accrued Expenses $21.55M $11.36M $12.31M
YoY Change 100.61% 3.08% 29.99%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $46.73M $16.48M $14.95M
YoY Change 201.88% 8.88% 3.55%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $4.100M $1.700M $1.700M
YoY Change 156.25% -10.53% -10.53%
Total Long-Term Liabilities $4.100M $1.700M $1.700M
YoY Change 156.25% -10.53% -10.53%
TOTAL LIABILITIES
Total Short-Term Liabilities $46.73M $16.48M $14.95M
Total Long-Term Liabilities $4.100M $1.700M $1.700M
Total Liabilities $50.84M $18.14M $16.69M
YoY Change 197.82% 6.23% 1.9%
SHAREHOLDERS EQUITY
Retained Earnings -$533.8M -$366.1M -$339.2M
YoY Change 34.7% 42.72% 49.1%
Common Stock $629.6M $528.6M $506.1M
YoY Change 17.72% 16.14% 12.95%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $95.53M $162.2M $166.9M
YoY Change
Total Liabilities & Shareholders Equity $146.4M $180.4M $183.6M
YoY Change -5.83% -16.27% -22.51%

Cashflow Statement

Concept 2018 Q1 2016 Q4 2016 Q3
OPERATING ACTIVITIES
Net Income -$38.46M -$26.94M -$25.43M
YoY Change 28.55% -7.27% -16.29%
Depreciation, Depletion And Amortization $170.0K $180.0K $180.0K
YoY Change -5.56% 5.88% 5.88%
Cash From Operating Activities -$34.65M -$20.00M -$20.33M
YoY Change 40.23% -1.86% -19.74%
INVESTING ACTIVITIES
Capital Expenditures $382.0K -$20.00K $0.00
YoY Change -96.08% -100.0%
Acquisitions
YoY Change
Other Investing Activities $2.870M $6.630M -$4.970M
YoY Change 421.82% -80.7% -111.12%
Cash From Investing Activities $2.484M $6.610M -$4.980M
YoY Change 351.64% -80.47% -111.18%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 429.0K 19.24M 31.48M
YoY Change 615.0% 1200.0% 78600.0%
NET CHANGE
Cash From Operating Activities -34.65M -20.00M -20.33M
Cash From Investing Activities 2.484M 6.610M -4.980M
Cash From Financing Activities 429.0K 19.24M 31.48M
Net Change In Cash -31.70M 5.850M 6.170M
YoY Change 31.6% -60.87% -67.96%
FREE CASH FLOW
Cash From Operating Activities -$34.65M -$20.00M -$20.33M
Capital Expenditures $382.0K -$20.00K $0.00
Free Cash Flow -$35.03M -$19.98M -$20.33M
YoY Change 0.55% -19.29%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q4 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
3681 sqft
CY2014Q4 kpti Operating Lease Scheduled Rent Payments Due
OperatingLeaseScheduledRentPaymentsDue
374000
CY2014Q4 kpti Operating Lease Scheduled Rent Payments Due
OperatingLeaseScheduledRentPaymentsDue
449000
CY2014Q1 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
29933 sqft
CY2014Q1 us-gaap Security Deposit
SecurityDeposit
400000
CY2014Q1 kpti Estimated Future Security Deposit
EstimatedFutureSecurityDeposit
200000
CY2018Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
49652828 shares
CY2015Q1 us-gaap Tenant Improvements
TenantImprovements
1616000
CY2017Q2 dei Entity Public Float
EntityPublicFloat
316146057
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
150609000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
206794000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
58358000
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
198365000
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11362000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
131636000
CY2016Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
163239000
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
480000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1845000
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
528617000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4751000
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-274000
CY2016Q4 us-gaap Assets
Assets
180385000
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
39000
CY2016Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
95949000
CY2016Q4 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear
0 Securities
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
194000
CY2016Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
125323000
CY2016Q4 us-gaap Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear
58 Securities
CY2016Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
125478000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49663000
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41887829 shares
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41887829 shares
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
130321000
CY2016Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
3344000
CY2016Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2016Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1666000
CY2016Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
280000
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
130321000
CY2016Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
15898000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
17004000
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3476000
CY2016Q4 us-gaap Liabilities
Liabilities
18142000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
180385000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16476000
CY2016Q4 us-gaap Long Term Investments
LongTermInvestments
45434000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
551000
CY2016Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
83000
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2084000
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2836000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4681000
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
479000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-366104000
CY2016Q4 us-gaap Short Term Investments
ShortTermInvestments
79889000
CY2017Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
148673000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
972000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
162243000
CY2016Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2016Q4 kpti Deferred Tax Assets Operating Loss Carryforwards Domestic And State And Local
DeferredTaxAssetsOperatingLossCarryforwardsDomesticAndStateAndLocal
91584000
CY2016Q4 kpti Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
6855000
CY2016Q4 kpti Deferred Tax Assets Tax Deferred Expense Reserves And Accruals And Other Temporary Differences
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOtherTemporaryDifferences
2491000
CY2016Q4 kpti Additional Area Included In Operating Sublease After Amendment
AdditionalAreaIncludedInOperatingSubleaseAfterAmendment
16234 sqft
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21445000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
148423000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2558000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
625017000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5665000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-217000
CY2017Q4 us-gaap Assets
Assets
180294000
CY2017Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3000
CY2017Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
96623000
CY2017Q4 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear
0 Securities
CY2017Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
256000
CY2017Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
106868000
CY2017Q4 us-gaap Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear
54 Securities
CY2017Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
107121000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
68997000
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49533150 shares
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49533150 shares
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2017Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
21921000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
134087000
CY2017Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
2211000
CY2017Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2017Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1363000
CY2017Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
303000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
134087000
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
29186000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
15748000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3982000
CY2017Q4 us-gaap Liabilities
Liabilities
50830000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
180294000
CY2015 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1778000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-92251000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1432000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
1091000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
1407000
CY2015 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-118434000
CY2015 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
26000
CY2015 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
366000
CY2015 us-gaap Depreciation And Amortization
DepreciationAndAmortization
634000
CY2015 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.32
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
49467000
CY2017Q4 us-gaap Long Term Investments
LongTermInvestments
29396000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
0
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
293000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
1390000
CY2017Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
133000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
6775000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1455000
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1754000
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2185000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4743000
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
200000
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
290000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-495341000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
1675513 shares
CY2017Q4 us-gaap Short Term Investments
ShortTermInvestments
77472000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
129464000
CY2017Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2017Q4 kpti Liability For Uncertain Tax Positions Current And Noncurrent
LiabilityForUncertainTaxPositionsCurrentAndNoncurrent
0
CY2017Q4 kpti Deferred Tax Assets Operating Loss Carryforwards Domestic And State And Local
DeferredTaxAssetsOperatingLossCarryforwardsDomesticAndStateAndLocal
84556000
CY2017Q4 kpti Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
16198000
CY2017Q4 kpti Deferred Tax Assets Tax Deferred Expense Reserves And Accruals And Other Temporary Differences
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOtherTemporaryDifferences
2386000
CY2014Q4 us-gaap Lessee Leasing Arrangements Operating Leases Term Of Contract
LesseeLeasingArrangementsOperatingLeasesTermOfContract
P5Y
CY2014Q1 kpti Number Of Additional Lease Terms Option To Renew
NumberOfAdditionalLeaseTermsOptionToRenew
1 Lease
CY2014Q1 kpti Lessee Leasing Arrangements Operating Leases Additional Extension Term
LesseeLeasingArrangementsOperatingLeasesAdditionalExtensionTerm
P5Y
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17057000
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
17057000
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21582000
CY2015 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.001 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.394 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.122 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.035 pure
CY2015 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-99000
CY2015 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.063 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.051 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.010 pure
CY2015 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-2000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-96676000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-118181000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-21409000
CY2015 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-500000
CY2015 us-gaap Increase Decrease In Prepaid Rent
IncreaseDecreaseInPrepaidRent
-213000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-118085000
CY2015 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2426000
CY2015 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
5766000
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
55000
CY2015 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
82000
CY2015 us-gaap Investment Income Interest
InvestmentIncomeInterest
897000
CY2015 us-gaap License And Services Revenue
LicenseAndServicesRevenue
250000
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-90823000
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-94029000
CY2015 us-gaap Operating Expenses
OperatingExpenses
119326000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
92700000
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-118181000
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-119076000
CY2015 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
895000
CY2015 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-86000
CY2015 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1033000
CY2015 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-167000
CY2015 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000
CY2015 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
305192000
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1416000
CY2015 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
616000
CY2015 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
215867000
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
97744000
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
17057000
CY2015 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
90830000
CY2015 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
616000
CY2015 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0
CY2015 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35619506 shares
CY2015 kpti Cash Received Related To Tenant Lease Incentives
CashReceivedRelatedToTenantLeaseIncentives
685000
CY2015 kpti Proceeds From Payments For Common Stock Issuance Net
ProceedsFromPaymentsForCommonStockIssuanceNet
92084000
CY2017 dei Amendment Flag
AmendmentFlag
false
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
20405000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
20405000
CY2017 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1187000
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
19334000
CY2017 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-128927000
CY2017 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
572000
CY2017 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.04 pure
CY2017 us-gaap Depreciation And Amortization
DepreciationAndAmortization
713000
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.81
CY2017 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2017 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017 dei Document Type
DocumentType
10-K
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.014 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Prior Year Income Taxes
EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
0.010 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.084 pure
CY2017 dei Document Period End Date
DocumentPeriodEndDate
2017-12-31
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.059 pure
CY2017 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
200000
CY2017 dei Entity Registrant Name
EntityRegistrantName
KARYOPHARM THERAPEUTICS INC.
CY2017 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2017 dei Entity Central Index Key
EntityCentralIndexKey
0001503802
CY2017 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.332 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.094 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.039 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.014 pure
CY2017 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2017 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2017 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-62000
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
24870000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-93241000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-128921000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-35680000
CY2017 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
21921000
CY2017 us-gaap Increase Decrease In Prepaid Rent
IncreaseDecreaseInPrepaidRent
280000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-128921000
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
63000
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
909000
CY2017 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
10070000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-342000
CY2017 us-gaap Investment Income Interest
InvestmentIncomeInterest
1698000
CY2017 us-gaap License And Services Revenue
LicenseAndServicesRevenue
1605000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
17108000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-73717000
CY2017 us-gaap Operating Expenses
OperatingExpenses
132143000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
75743000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-128984000
CY2017 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 Segments
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-130538000
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1617000
CY2017 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
154000
CY2017 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1198000
CY2017 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-97000
CY2017 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-81000
CY2017 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
98374000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
62000
CY2017 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
858000
CY2017 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
115544000
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
107273000
CY2017 us-gaap Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
21916000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
20405000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
1958210 shares
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
858000
CY2017 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0
CY2017 dei Trading Symbol
TradingSymbol
KPTI
CY2017 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
45899784 shares
CY2017 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
3766000
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Use of Estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"> On an ongoing basis, the Company&#x2019;s management evaluates its estimates, including estimates related to clinical trial accruals, stock-based compensation expense, and reported amounts of expenses during the reported period. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.</p> </div>
CY2017 kpti Proceeds From Payments For Common Stock Issuance Net
ProceedsFromPaymentsForCommonStockIssuanceNet
74885000
CY2017 kpti Operating Loss And Tax Credit Carryforwards Limitations Period Over Which Cumulative Changes In Ownership Interest Of Significant Shareholders Considered
OperatingLossAndTaxCreditCarryforwardsLimitationsPeriodOverWhichCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered
P3Y
CY2016 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-63000
CY2016 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.085 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.031 pure
CY2017 kpti Operating Loss And Tax Credit Carryforwards Limitations Threshold Percentage Of Cumulative Changes In Ownership Interest Of Significant Shareholders Considered
OperatingLossAndTaxCreditCarryforwardsLimitationsThresholdPercentageOfCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered
0.50 pure
CY2017 kpti Number Of Future Milestones
NumberOfFutureMilestones
0 pure
CY2017 kpti Tax Cuts And Jobs Act Of2017 Change In Tax Rate Reduction In Deferred Tax Assets
TaxCutsAndJobsActOf2017ChangeInTaxRateReductionInDeferredTaxAssets
42763000
CY2016 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
39000
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
22283000
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
22283000
CY2016 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1199000
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-8695000
CY2016 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-109569000
CY2016 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
491000
CY2016 us-gaap Depreciation And Amortization
DepreciationAndAmortization
717000
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.92
CY2016 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.001 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.251 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Prior Year Income Taxes
EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
-0.055 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.048 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.033 pure
CY2016 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
10000
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
27349000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-27059000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-27349000
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
23948000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-82510000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-109438000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-26928000
CY2016 us-gaap Increase Decrease In Prepaid Rent
IncreaseDecreaseInPrepaidRent
206000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-109438000
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
139000
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
945000
CY2016 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
368000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
120000
CY2016 us-gaap Investment Income Interest
InvestmentIncomeInterest
1284000
CY2016 us-gaap License And Services Revenue
LicenseAndServicesRevenue
154000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
24595000
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-84391000
CY2016 us-gaap Operating Expenses
OperatingExpenses
110886000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
51164000
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-109577000
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-110732000
CY2016 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1294000
CY2016 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-26000
CY2016 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1150000
CY2016 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
34000
CY2016 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
10000
CY2016 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
134700000
CY2016 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
39000
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
70000
CY2016 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
630000
CY2016 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
159365000
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
86938000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
22283000
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
630000
CY2016 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0
CY2016 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37523051 shares
CY2016 kpti Proceeds From Payments For Common Stock Issuance Net
ProceedsFromPaymentsForCommonStockIssuanceNet
50573000
CY2016 kpti Reimbursable Cost Of Expense Period
ReimbursableCostOfExpensePeriod
P1Y
CY2015Q1 kpti Operating Leases Allowance For Improvements
OperatingLeasesAllowanceForImprovements
1616000
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.71
CY2017Q1 us-gaap License And Services Revenue
LicenseAndServicesRevenue
68000
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
30347000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-29917000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-30279000
CY2017Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
385000
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.75
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
25790000
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-29752000
CY2017Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
383000
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.69
CY2016Q3 us-gaap License And Services Revenue
LicenseAndServicesRevenue
48000
CY2016Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
290000
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.84
CY2016Q2 us-gaap License And Services Revenue
LicenseAndServicesRevenue
59000
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
30535000
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-30158000
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-30476000
CY2016Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
318000
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.64
CY2017Q2 us-gaap License And Services Revenue
LicenseAndServicesRevenue
3000
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
29755000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-29387000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-25425000
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-25742000
CY2016Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
317000
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.65
CY2017Q3 us-gaap License And Services Revenue
LicenseAndServicesRevenue
0
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
31055000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-30640000
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-31055000
CY2017Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
428000
CY2016Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.65
CY2016Q4 us-gaap License And Services Revenue
LicenseAndServicesRevenue
47000
CY2016Q4 us-gaap Operating Expenses
OperatingExpenses
27212000
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
-26935000
CY2016Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-27165000
CY2016Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
369000
CY2017Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.80
CY2017Q4 us-gaap License And Services Revenue
LicenseAndServicesRevenue
1534000
CY2017Q4 us-gaap Operating Expenses
OperatingExpenses
40986000
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-39040000
CY2017Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-39452000
CY2017Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
421000

Files In Submission

Name View Source Status
0001193125-18-084024-index-headers.html Edgar Link pending
0001193125-18-084024-index.html Edgar Link pending
0001193125-18-084024.txt Edgar Link pending
0001193125-18-084024-xbrl.zip Edgar Link pending
d529132d10k.htm Edgar Link pending
d529132dex1030.htm Edgar Link pending
d529132dex121.htm Edgar Link pending
d529132dex211.htm Edgar Link pending
d529132dex231.htm Edgar Link pending
d529132dex311.htm Edgar Link pending
d529132dex312.htm Edgar Link pending
d529132dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g529132g02u19.jpg Edgar Link pending
g529132g06s23.jpg Edgar Link pending
g529132g15k45.jpg Edgar Link pending
g529132g19j32.jpg Edgar Link pending
g529132g35p46.jpg Edgar Link pending
g529132g59h21.jpg Edgar Link pending
g529132g81r88.jpg Edgar Link pending
g529132g93e07.jpg Edgar Link pending
kpti-20171231.xml Edgar Link completed
kpti-20171231.xsd Edgar Link pending
kpti-20171231_cal.xml Edgar Link unprocessable
kpti-20171231_def.xml Edgar Link unprocessable
kpti-20171231_lab.xml Edgar Link unprocessable
kpti-20171231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending